title: [Postoperative radio-chemotherapy in locally advanced gastric cancer].
abstract: BACKGROUND
  Overall 5 years survival for surgically excised gastric cancer is 30%. Adjuvant treatment may improve the surgical results.
  
  
  OBJECTIVE
  To assess treatment results and toxicity in patients with surgically excised gastric cancer, treated with adjuvant radiotherapy and concomitant continuous 5-Fluorouracil (5-FU).
  
  
  METHODS
  Forty one patients aged 32 to 73 years (29 males) with stage II-IVA gastric cancer, subjected to a total or subtotal gastrectomy and D2 nodal dissection between 1997 to 2006, were studied. They received adjuvant radiotherapy to the gastric bed and draining nodes in a total dose of 50.4 Gy in 28 fractions and chemotherapy with continuous infusion 5-FU, 200 mg/m(2)/day. Results were compared to historical controls matched according to demographic parameters and tumor characteristics.
  
  
  RESULTS
  Eighteen patients were in stage II, 10 in stage IIIA, nine in stage IIIB and four in stage IVA. Twelve patients had an NO nodal status, 15 were NI, nine were N2 and five were N3. After a mean follow up of 32 months, 26 patients (63%) were alive. Five year overall survival was 49.6% for surgery plus radiochemotherapy compared to 30.7% for the historical group subjected only to surgery (p =0.002). Radiotherapy was associated with grade 1-2 toxicity and treatment was completed without interruptions in all patients. Chemotherapy was delayed temporarily in 3 patients.
  
  
  CONCLUSIONS
  Adjuvant radio-chemotherapy improved overall survival in gastric cancer, compared to historical controls subjected only to surgical treatment.
authors.affiliation: Departamento de Hematología-Oncología, Programa de Cancer, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Garrido
authors.forename: Marisa
authors.initials: M
authors.lastname: Bustos
authors.forename: Eric
authors.initials: E
authors.lastname: Orellana
authors.forename: Jorge
authors.initials: J
authors.lastname: Madrid
authors.forename: Héctor
authors.initials: H
authors.lastname: Galindo
authors.forename: César
authors.initials: C
authors.lastname: Sánchez
authors.forename: Fernando
authors.initials: F
authors.lastname: Pimentel
authors.forename: Sergio
authors.initials: S
authors.lastname: Guzmán
authors.forename: Luis
authors.initials: L
authors.lastname: Ibáñez
authors.forename: Jean Michel
authors.initials: JM
authors.lastname: Butte
authors.forename: Manuel
authors.initials: M
authors.lastname: Alvarez
authors.forename: Pelayo
authors.initials: P
authors.lastname: Besa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011829:Radiation Dosage; D018714:Radiotherapy, Adjuvant; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D015996:Survival Rate
chemical_list: D005472:Fluorouracil